Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

A collaboration between the Russell group (Chemistry and Pharmacology) and the Davies group (Physiology, Anatomy and Genetics) has identified, via a chemical proteomics and phenotypic profiling strategy, the arylhydrocarbon receptor (AhR) as the molecular target of ezutromid, the utrophin modulator that recently completed a Phase 2 clinical trial in Duchenne muscular dystrophy patients.

Research results have been published in Angewandte Chemie.

Ezutromid (formerly SMT C1100) was identified through phenotypic screening approach, and developed as a first-in-class utrophin modulator for the treatment of the severe muscle wasting disease Duchenne muscular dystrophy (DMD). The clinical trial showed promising efficacy and evidence of target engagement after 24 weeks of treatment, but these effects were not seen after the full 48 weeks of the trial. Without knowledge of the mechanism of action of ezutromid, it was difficult to rationalise the lack of sustained clinical efficacy, and development of ezutromid was discontinued.

In this work, we demonstrate through a series of target identification and validation studies that ezutromid binds to AhR with high affinity, and antagonism of AhR by ezutromid leads to utrophin upregulation, thereby confirming AhR as a viable target for utrophin functional replacement therapies. This work paves the way for the first target-based disease modifying drug discovery program in DMD.

See https://onlinelibrary.wiley.com/doi/abs/10.1002/anie.201912392

Similar stories

Consequences of Tau pathology on hippocampal pyramidal neurons and network activity in ageing mice

Pathological hyperphosphorylated forms of the microtubule-associated binding protein Tau (pTau) are commonly found in people with neurodegenerative diseases, including Alzheimer’s disease, Corticobasal degeneration, and Progressive supranuclear palsy.

Welcome to the 2022/23 academic year in Pharmacology!

At the start of this year, we have welcomed 23 new MSc in Pharmacology students, 13 new MSc(Res) and DPhil students and around a dozen additional project and visiting students from other Departments and other Universities. Some of these new starters joined existing staff, students and visitors in the Department for the first of a series of group photographs, to be taken every 6 months for our archives.

New Platt group paper explores links between Mycobacteria tuberculosis and Niemann-Pick Type C disease

Congratulations to Yuzhe Weng, a DPhil student in the Platt lab, who is first author on new paper published by the group in Nature Communications. Mycobacteria tuberculosis (Mtb), the causative agent of tuberculosis (TB), has the ability to invade, persist and replicate within host cells, which is key to its success as a pathogen. However, the mechanisms that underlie this strategy remain poorly defined.

PROFESSOR REBECCA SITSAPESAN 1959-2022

We were sad to learn that our dear colleague Rebecca has died just a few days before what would have been her 63rd birthday.

New high-resolution imaging provides clue to SARS-CoV-2 leap to humans

A new paper, published this week in the journal Science, highlights cutting-edge imaging techniques used by the group of Professor Ben Davis to investigate the binding of SARS-CoV-2 to human cells.

Dr Mehmood Khan joins Pharmacology as a Visiting Fellow

We are delighted to announce the appointment of Dr Mehmood Khan as a Visiting Fellow in the Department